Sichuan Tongyuan Pharmaceutical Co. Ltd.

Main purpose To compare the differences in the extent and rate of absorption of repaglinide tablets (1 mg) provided by Sichuan Xuhui Pharmaceutical Co., Ltd. and repaglinide tablets (1 mg, trade name: Novolong®) licensed by Novo Nordisk A/S in healthy adults under fasting and postprandial administration conditions, and to evaluate their bioequivalence. Secondary purpose To evaluate the safety of repaglinide tablets (1 mg) provided by Sichuan Xuhui Pharmaceutical Co., Ltd. and repaglinide tablets (1 mg, trade name: Novolong®) licensed by Novo Nordisk A/S under fasting and postprandial administration conditions.

The main purpose of the study is to study the pharmacokinetics of the test preparation sildenafil citrate orodisintegrating tablets (specification: 50 mg, produced by Sichuan Xuhui Pharmaceutical Co., Ltd.) and the reference preparation sildenafil citrate orodisintegrating tablets (Viagra®) (specification: 50 mg, produced by Fareva Amboise) in healthy subjects after a single oral administration under fasting conditions, and to evaluate the bioequivalence of the two preparations when taken orally under fasting conditions. The secondary purpose of the study is to evaluate the safety of the test preparation sildenafil citrate orodisintegrating tablets (specification: 50 mg) and the reference preparation sildenafil citrate orodisintegrating tablets (Viagra®) (specification: 50 mg) in healthy subjects.

To observe the in vivo kinetics of levoamlodipine besylate tablets after a single oral administration in healthy Chinese subjects, estimate the corresponding pharmacokinetic parameters, and conduct bioequivalence evaluation using amlodipine besylate tablets (Norvasc®) produced by Pfizer as the reference preparation.